<DOC>
	<DOC>NCT00612105</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy of retigabine vs. placebo in reducing pain associated with post-herpetic neuralgia.</brief_summary>
	<brief_title>Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)</brief_title>
	<detailed_description>This is a Phase 2a proof of concept study evaluating the safety/efficacy of retigabine vs. placebo in patients with post-herpetic neuralgia. After screening, patients will enter a maximum 6 week titration period followed by a 4 week maintenance period and a 3 week taper phase.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Ability to provide informed consent Male or female subjects 1885 years of age PHN for more than 6 months after the healing of herpes zoster skin rash Has a pain score at screening and randomization that qualifies Other significant pain that may potentially confound PHN pain assessment Previous neurolytic or neurosurgical therapy for PHN Subject has evidence of a progressive central nervous system (CNS) disease (e.g. CNS lupus, tumors, multiple sclerosis, Alzheimer's), lesion, or encephalopathy Significant psychiatric or neuropsychiatric disorders including but not limited to severe depression, bipolar disorder or schizophrenia spectrum disorder, history of suicide attempt, or recent history of suicidal ideation Has clinically significant abnormalities on physical examination, vital signs, ECG, or laboratory tests at the screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Postherpetic Neuralgia, PHN, Shingles,</keyword>
</DOC>